First-in-Human vaccine tested for devastating brain diseases
NCT ID NCT05634876
Summary
This small, early-stage study tested the safety and immune response of an experimental vaccine called UB-312 in people with Parkinson's disease or multiple system atrophy. The goal is to see if the vaccine can safely train the body's immune system to target harmful proteins in the brain linked to these conditions. The study involved 8 participants and focused on measuring safety and antibody levels in the blood and spinal fluid.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NYU Langone Health
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.